ZP-3022 is a synthetic GLP-1 analog peptide — a lab-made molecule designed to mimic glucagon-like peptide-1, a natural gut hormone involved in blood sugar regulation. It is studied in preclinical research for its potential effects on beta-cell proliferation and metabolic function. It is not approved for human therapeutic use and is classified as a research-use-only compound.

How does ZP-3022 work?

ZP-3022 is believed to bind to the GLP-1 receptor found on pancreatic beta cells. When it docks there, it triggers intracellular signals that may encourage beta cells to multiply and survive longer. It is also engineered to be more stable than natural GLP-1, which breaks down within minutes in the body, giving it a potentially longer window of activity in research models.

What is ZP-3022 used for in research?

Researchers study ZP-3022 primarily for its potential to promote beta-cell proliferation — essentially growing more of the insulin-producing cells in the pancreas. It is also examined in the context of metabolic disorders, obesity models, insulin secretion dynamics, and as a structural template for understanding how to design longer-lasting GLP-1 mimetic compounds.

How is ZP-3022 dosed?

Dosing varies by experimental model, species, body weight, and the research question being asked. There is no single standard protocol. Check the dosage chart on this page for reported preclinical dose ranges, and use the on-page calculator to scale by subject weight. These figures are reference tools for research protocol design only — not clinical recommendations.

How do you reconstitute ZP-3022?

ZP-3022 typically comes as a freeze-dried powder. To reconstitute it, slowly add sterile bacteriostatic water or a dilute acetic acid solution to reach your target concentration. Roll the vial gently — never shake. Store the reconstituted solution at 4°C and use within a few weeks, or freeze aliquots at −20°C. Avoid repeated freeze-thaw cycles, which can degrade the peptide.

ZP-3022 has not been approved by any regulatory agency for human use, and its full safety profile in humans is not established. It is a research-use-only compound intended for controlled laboratory settings. No safety conclusions for human subjects can be drawn from available preclinical data. Researchers should follow all institutional biosafety protocols when handling this compound.

ZP-3022 Dosage Chart, Protocol & Calculator

A GLP-1 analog studied for beta-cell proliferation.

Objetivo	Dosis	Frecuencia	Duración	Evidencia	Fuente
Los datos de dosis citados de este compuesto se están compilando.

What is ZP-3022?

ZP-3022 is a synthetic peptide — a small chain of amino acids built in a lab — that belongs to the GLP-1 analog family. GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases after you eat. It plays a big role in managing blood sugar. ZP-3022 is designed to mimic and extend some of those effects, with a particular focus on the cells that make insulin.

This compound is strictly a research-use-only molecule. It is not approved as a medicine, and nothing here should be read as medical advice. Scientists study it to better understand how the body regulates blood sugar and how pancreatic cells can be encouraged to grow and function.

How ZP-3022 Works

Think of the pancreas as a factory. Inside that factory are special workers called beta cells. Their one job is to produce insulin — the key that unlocks your cells so sugar can enter and be used for energy. In conditions like type 2 diabetes, you can run short of these workers, or they stop functioning well.

GLP-1 analogs like ZP-3022 are thought to act like a supervisor sending a signal to the factory floor. They bind to the GLP-1 receptor — a docking station found on beta cells — and trigger a chain of events inside the cell. The result researchers are most interested in: the signal may tell beta cells to multiply (that's proliferation) and to stay alive longer instead of dying off (that's reduced apoptosis).

ZP-3022 is also engineered for stability. Natural GLP-1 breaks down in the bloodstream within minutes. By tweaking the peptide's structure, researchers aim to make it last longer and hit its target more effectively.

What the Research Shows

Because no numbered sources have been provided for this page, we can outline the general research landscape without making specific cited claims.

Preclinical studies on GLP-1 analogs as a class — including compounds like ZP-3022 — have explored several areas:

Beta-cell mass: Researchers have looked at whether GLP-1 receptor activation can increase the number of functional beta cells in animal models of diabetes.
Insulin secretion: Studies examine whether the compound boosts insulin release in a glucose-dependent way — meaning it only kicks in when blood sugar is actually elevated, which is a desirable safety feature.
Body weight and food intake: Many GLP-1 analogs are associated with reduced appetite and lower food intake in animal models, making them interesting to metabolic researchers.
Durability of action: Researchers compare how long ZP-3022 stays active compared with native GLP-1, since a longer half-life means less frequent dosing in experimental protocols.

It is important to emphasize: most of this work is early-stage, conducted in cell cultures or rodent models. Human clinical data on ZP-3022 specifically is limited, and no regulatory body has approved it for therapeutic use.

What ZP-3022 Is Being Studied For

Research interest in ZP-3022 centers on a few key questions in metabolic biology:

Diabetes models: Can it restore or preserve beta-cell populations in animals with induced diabetes?
Obesity research: Does it influence energy balance, fat storage, or appetite-regulating hormones?
Regenerative biology: Could it serve as a tool to understand how pancreatic tissue regenerates?
Drug design: As a structural template, what does it teach chemists about building better, longer-lasting GLP-1 mimetics?

None of these research uses constitute a treatment or therapy. Scientists use compounds like ZP-3022 as investigational tools to ask and answer biological questions in controlled laboratory settings.

How ZP-3022 Is Dosed in Research

Dosing for research peptides like ZP-3022 depends heavily on the experimental model — species, body weight, route of administration, and the specific endpoint being measured. There is no single universal protocol. For a full breakdown of the dose ranges and schedules reported in preclinical literature, refer to the dosage chart on this page. You can also use the on-page calculator to adjust figures based on subject weight. Always treat these numbers as starting points for protocol design, not clinical recommendations.

Mixing and Storing ZP-3022

ZP-3022 typically arrives as a lyophilized powder — that just means it has been freeze-dried to make it shelf-stable. Before use in any experiment, it needs to be reconstituted, which means dissolving it back into a liquid.

Here are the general principles researchers follow:

Solvent: Sterile bacteriostatic water or a dilute acetic acid solution (around 0.1–1%) is commonly used for GLP-1 peptides. Always check the specific guidance for your batch.
Gentle mixing: Roll the vial slowly between your palms or let it sit. Never shake vigorously — this can break the peptide's structure.
Volume: Add solvent gradually to reach your target concentration. Common working concentrations in research are in the microgram-per-milliliter range.
Storage after mixing: Reconstituted peptide should be kept refrigerated (around 4°C / 39°F) and used within a few weeks. For longer storage, aliquot into small portions and freeze at −20°C or colder. Avoid repeated freeze-thaw cycles.
Dry powder storage: Unopened lyophilized vials are generally stable at room temperature short-term but should be kept away from moisture, heat, and direct light. Long-term dry storage is best at −20°C.

Always work under sterile conditions and follow your institution's guidelines for handling research compounds.

ZP-3022 Guía & Tabla de Dosis